The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease
- PMID: 25823812
- PMCID: PMC4441106
- DOI: 10.1016/j.ejphar.2015.03.040
The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease
Abstract
Ethics on animal use in science in Western society is based on utilitarianism, weighing the harms and benefits to the animals involved against those of the intended human beneficiaries. The 3Rs concept (Replacement, Reduction, Refinement) is both a robust framework for minimizing animal use and suffering (addressing the harms to animals) and a means of supporting high quality science and translation (addressing the benefits). The ambiguity of basic research performed early in the research continuum can sometimes make harm-benefit analysis more difficult since anticipated benefit is often an incremental contribution to a field of knowledge. On the other hand, benefit is much more evident in translational research aimed at developing treatments for direct application in humans or animals suffering from disease. Though benefit may be easier to define, it should certainly not be considered automatic. Issues related to model validity seriously compromise experiments and have been implicated as a major impediment in translation, especially in complex disease models where harms to animals can be intensified. Increased investment and activity in the 3Rs is delivering new research models, tools and approaches with reduced reliance on animal use, improved animal welfare, and improved scientific and predictive value.
Keywords: Animal welfare; Drug development; Reduction; Refinement; Replacement; Utilitarianism.
Copyright © 2015 Elsevier B.V. All rights reserved.
Figures
References
-
- AAALAC, 2014. The AAALAC International Accreditation Program. 〈http://www.aaalac.org/accreditation/〉.
-
- Administration of Quality Supervision, Inspection and Quarantine of the People׳s Republic of China and Standardization Administration of the People׳s Republic of China, 2013. National Standard of the People׳s Republic of China, Laboratory Animal Facilities – General Requirements for Quality and Competence, Draft Standard for Approval 12th April, 2013.
-
- AstraZeneca, 2014. Our 3Rs Commitment. 〈http://www.astrazeneca.com/Responsibility/Research-ethics/Animal-resear....
-
- Bailey J., Thew M., Balls M. An analysis of the use of animal models in predicting human toxicology and drug safety. Altern. Lab. Anim. 2014;42:181–199. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources